Voluntary nationwide recall: Brexafemme
Oct. 2023Pharmacy Updates
Scynexis, Inc. is recalling two lots of Brexafemme (ibrexafungerp tablets) due to potential cross-contamination with a nonantibacterial ß-lactam drug substance in the ibrexafungerp citrate used to manufacture the Brexafemme tablets. This drug is used as an antifungal for the treatment of vulvovaginal candidiasis (VVC) and the reduction of the incidence of recurrent vulvovaginal candidiasis (RVVC). Read the full text of the voluntary Brexafemme recall.
Recent Announcements
UPMC Health Plan Tapestry Link resources available
UPMC Health Plan Tapestry Link will launch on Tuesday, Dec. 1, 2026. To help ease your transition to the new platform, we have developed the following resources:Nov. 2026Important Notices
Changes to inpatient denial and OBS claim billing
We will soon transition to the Epic® platform. This change will align our claims processing with industry standards by adjudicating claims based on the level of care authorized. As this transition approaches, please keep the following areas in mind:Nov. 2026
Provider Services does not accept automated calls
Provider Services does not accept automated callsNov. 2026Important Notices